Ubs Group Ag Rockwell Medical, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Rockwell Medical, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 11,719 shares of RMTI stock, worth $11,367. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,719

Previous 14,596 19.71%

Holding current value

$11,367

Previous $16,000 43.75%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$0.79 - $1.23 $2,272 - $3,538	-2,877 Reduced 19.71%	11,719 $9,000
Q1 2025 May 13, 2025	SELL	$1.13 - $2.33 $6,340 - $13,073	-5,611 Reduced 27.77%	14,596 $16,000
Q4 2024 Feb 14, 2025	SELL	$2.01 - $4.65 $138,714 - $320,905	-69,012 Reduced 77.35%	20,207 $41,000
Q3 2024 Nov 14, 2024	BUY	$1.67 - $4.4 $146,610 - $386,280	87,791 Added 6147.83%	89,219 $354,000
Q2 2024 Aug 13, 2024	SELL	$1.45 - $1.92 $2,433 - $3,221	-1,678 Reduced 54.02%	1,428 $2,000
Q1 2024 May 13, 2024	BUY	$1.23 - $1.86 $3,709 - $5,609	3,016 Added 3351.11%	3,106 $5,000
Q4 2023 Feb 09, 2024	SELL	$1.58 - $2.44 $5,940 - $9,174	-3,760 Reduced 97.66%	90 $0
Q3 2023 Nov 09, 2023	SELL	$1.83 - $6.19 $107 - $365	-59 Reduced 1.51%	3,850 $8,000
Q2 2023 Aug 11, 2023	SELL	$1.8 - $5.46 $6,861 - $20,813	-3,812 Reduced 49.37%	3,909 $21,000
Q1 2023 May 12, 2023	SELL	$1.03 - $2.62 $2,377 - $6,046	-2,308 Reduced 23.01%	7,721 $13,000
Q4 2022 Feb 08, 2023	BUY	$0.84 - $1.39 $3,580 - $5,924	4,262 Added 73.9%	10,029 $10,000
Q3 2022 Nov 10, 2022	BUY	$1.2 - $2.11 $6,812 - $11,978	5,677 Added 6307.78%	5,767 $7,000
Q2 2022 Aug 10, 2022	BUY	$1.28 - $4.84 $115 - $435	90 New	90 $0

Others Institutions Holding RMTI

# of Institutions

Shares Held

5.93M

Call Options Held

129K

Put Options Held

10.4K

View Full List

About ROCKWELL MEDICAL, INC.

Ticker RMTI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 10,675,200
Market Cap $10.4M
Description
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iro...

More about RMTI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account